Tags

Type your tag names separated by a space and hit enter

Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study.
Cardiology. 2008; 111(4):219-28.C

Abstract

BACKGROUND

Patients at high risk of cardiovascular disease frequently fail to reach recommended low-density lipoprotein cholesterol (LDL-C) goals, partly because statin doses are not titrated to optimal effect. The ECLIPSE study was designed to compare the efficacy and safety of force-titrated treatment with rosuvastatin (10-40 mg) with that of atorvastatin (10-80 mg) in high-risk patients with hypercholesterolemia.

METHODS

In this 24-week, open-label, randomized, multinational, parallel-group study, 1,036 patients were randomized to rosuvastatin (n = 522) or atorvastatin (n = 514).

RESULTS

At all time points, a significantly greater percentage of patients on rosuvastatin treatment achieved the NCEP ATP III LDL-C goal of <100 mg/dl (2.5 mmol/l), the 2003 European LDL-C target of <2.5 or 3.0 mmol/l (100 or 115 mg/dl) and the LDL-C goal of <70 mg/dl (1.8 mmol/l), a goal suggested for very high-risk patients (p < 0.001 for all). Rosuvastatin also achieved significantly greater improvements in components of the atherogenic lipid profile versus atorvastatin. Both treatments were well tolerated.

CONCLUSION

Rosuvastatin titrated across its recommended dose range provides a more favorable effect on lipoprotein variables than atorvastatin, enabling more high-risk patients to achieve recommended LDL-C goals.

Authors+Show Affiliations

Aarhus Sygehus University Hospital, Aarhus, Denmark.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18434729

Citation

Faergeman, Ole, et al. "Efficacy and Tolerability of Rosuvastatin and Atorvastatin when Force-titrated in Patients With Primary Hypercholesterolemia: Results From the ECLIPSE Study." Cardiology, vol. 111, no. 4, 2008, pp. 219-28.
Faergeman O, Hill L, Windler E, et al. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology. 2008;111(4):219-28.
Faergeman, O., Hill, L., Windler, E., Wiklund, O., Asmar, R., Duffield, E., & Sosef, F. (2008). Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology, 111(4), 219-28. https://doi.org/10.1159/000127442
Faergeman O, et al. Efficacy and Tolerability of Rosuvastatin and Atorvastatin when Force-titrated in Patients With Primary Hypercholesterolemia: Results From the ECLIPSE Study. Cardiology. 2008;111(4):219-28. PubMed PMID: 18434729.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. AU - Faergeman,Ole, AU - Hill,Laurie, AU - Windler,Eberhard, AU - Wiklund,Olov, AU - Asmar,Roland, AU - Duffield,Emma, AU - Sosef,Froukje, AU - ,, Y1 - 2008/04/23/ PY - 2007/08/17/received PY - 2007/11/02/accepted PY - 2008/4/25/pubmed PY - 2009/1/24/medline PY - 2008/4/25/entrez SP - 219 EP - 28 JF - Cardiology JO - Cardiology VL - 111 IS - 4 N2 - BACKGROUND: Patients at high risk of cardiovascular disease frequently fail to reach recommended low-density lipoprotein cholesterol (LDL-C) goals, partly because statin doses are not titrated to optimal effect. The ECLIPSE study was designed to compare the efficacy and safety of force-titrated treatment with rosuvastatin (10-40 mg) with that of atorvastatin (10-80 mg) in high-risk patients with hypercholesterolemia. METHODS: In this 24-week, open-label, randomized, multinational, parallel-group study, 1,036 patients were randomized to rosuvastatin (n = 522) or atorvastatin (n = 514). RESULTS: At all time points, a significantly greater percentage of patients on rosuvastatin treatment achieved the NCEP ATP III LDL-C goal of <100 mg/dl (2.5 mmol/l), the 2003 European LDL-C target of <2.5 or 3.0 mmol/l (100 or 115 mg/dl) and the LDL-C goal of <70 mg/dl (1.8 mmol/l), a goal suggested for very high-risk patients (p < 0.001 for all). Rosuvastatin also achieved significantly greater improvements in components of the atherogenic lipid profile versus atorvastatin. Both treatments were well tolerated. CONCLUSION: Rosuvastatin titrated across its recommended dose range provides a more favorable effect on lipoprotein variables than atorvastatin, enabling more high-risk patients to achieve recommended LDL-C goals. SN - 1421-9751 UR - https://www.unboundmedicine.com/medline/citation/18434729/Efficacy_and_tolerability_of_rosuvastatin_and_atorvastatin_when_force_titrated_in_patients_with_primary_hypercholesterolemia:_results_from_the_ECLIPSE_study_ L2 - https://www.karger.com?DOI=10.1159/000127442 DB - PRIME DP - Unbound Medicine ER -